Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
10:28:00 EST Sun 08 Feb 2026
Enter Symbol
or Name
USA
CA



Nova Mentis Life Science Corp
Symbol NOVA
Shares Issued 147,168,660
Close 2024-01-03 C$ 0.02
Market Cap C$ 2,943,373
Recent Sedar+ Documents

Nova Mentis appoints Hochwimmer as director

2024-01-03 16:43 ET - News Release

Subject: Nova Mentis Life Science - Jan 3 NR Word Document File: '\\swfile\EmailIn\20240103 133542 Attachment 2024_01_03 Nova NR change of directors and officers FINAL.docx' 1 Nova Mentis Announces Change of Directors and Officers Vancouver, British Columbia - January 03, 2023 - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company") announces the appointment of Dr. Georg Hochwimmer to the Company's Board of Directors, effective December 29, 2023. Dr. Hochwimmer is Chief Analyst at General Research, GmbH, a leading Munich-based securities research and analysis firm. Dr. Hochwimmer is a noted business consultant and academic responsible for aiding in the development of several highly profitable companies throughout Europe. He serves as the CEO of supraMAT Technologies AG, which is a business incubator for German technology companies. He founded leading German technical start-ups, such as NGP Polymers, SmartDyelivery and Trophosys. He is also a managing director of Microdrop Technologies, which is a globally leading 3D micro-printing company. Dr. Hochwimmer has earned advanced degrees in chemistry and mechanical engineering. The Company further announces the resignation of Jacqueline McConnell as Chief Operating Officer and Director of the Company, effective December 29, 2023. Ms. McConnell will continue on with Nova as a consultant, assisting the company in its clinical trial and other potential opportunities. The Board would like to thank Ms. McConnell for her involvement with Nova and wishes her the best in future endeavors. About Nova Mentis Life Science Corp. Nova Mentis Life Science Corp. is a Canadian-based biotechnology company and global leader in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova is the first biotech company to achieve orphan drug designation in both the United States and European Union for the use of psilocybin in the treatment of fragile X syndrome (FXS). NOVA's goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder (ASD) and FXS. For further information on the Company, please visit www.novamentis.ca or email info@novamentis.ca. On Behalf of the Board Will Rascan, President & CEO Nova Mentis Life Science Corp. Phone: 778-819-0244 Toll Free: 1-833-542-5323 Twitter: @novamentislsc Instagram: @novamentislsc Facebook: @novamentislsc Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release contains statements that constitute "forward-looking statements." Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Nova Mentis Life Science's actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.

© 2026 Canjex Publishing Ltd. All rights reserved.